Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	insulin receptor binding	IRS4 IGF1R PDPK2P PHIP	1.66e-06	30	58	4	GO:0005158
GeneOntologyMolecularFunction	phosphatidylinositol 3-kinase binding	FLT3 IRS4 IGF1R	2.64e-04	43	58	3	GO:0043548
GeneOntologyBiologicalProcess	positive regulation of fibroblast proliferation	BMI1 EGFR PRKDC PHIP MYB	3.73e-06	85	57	5	GO:0048146
GeneOntologyBiologicalProcess	spleen development	FLT3 BCL2 PRKDC MYB	1.29e-05	52	57	4	GO:0048536
GeneOntologyBiologicalProcess	hematopoietic progenitor cell differentiation	FLT3 CHD2 BCL2 PRKDC THSD1 MYB	1.70e-05	197	57	6	GO:0002244
GeneOntologyBiologicalProcess	B cell differentiation	FLT3 INHA DOCK10 BCL2 PRKDC MYB	1.91e-05	201	57	6	GO:0030183
GeneOntologyBiologicalProcess	peptidyl-serine phosphorylation	TTBK2 MLXIPL EGFR BCL2 PRKDC PDPK2P PHIP	2.11e-05	307	57	7	GO:0018105
GeneOntologyBiologicalProcess	peptidyl-serine modification	TTBK2 MLXIPL EGFR BCL2 PRKDC PDPK2P PHIP	2.70e-05	319	57	7	GO:0018209
GeneOntologyBiologicalProcess	homeostasis of number of cells	BMI1 FLT3 INHA DOCK10 ALAS1 BCL2 PRKDC MYB	3.03e-05	448	57	8	GO:0048872
GeneOntologyBiologicalProcess	regulation of fibroblast proliferation	BMI1 EGFR PRKDC PHIP MYB	3.55e-05	135	57	5	GO:0048145
GeneOntologyBiologicalProcess	B cell activation	BMI1 FLT3 INHA DOCK10 BCL2 PRKDC MYB	4.13e-05	341	57	7	GO:0042113
GeneOntologyBiologicalProcess	lymphoid progenitor cell differentiation	FLT3 BCL2 PRKDC	4.97e-05	26	57	3	GO:0002320
GeneOntologyBiologicalProcess	fibroblast proliferation	BMI1 EGFR PRKDC PHIP MYB	7.98e-05	160	57	5	GO:0048144
GeneOntologyBiologicalProcess	lymphocyte differentiation	BMI1 FLT3 INHA DOCK10 BCL2 PRKDC BTN2A1 MYB	1.08e-04	537	57	8	GO:0030098
GeneOntologyBiologicalProcess	B cell lineage commitment	BCL2 PRKDC	1.12e-04	6	57	2	GO:0002326
GeneOntologyBiologicalProcess	multicellular organismal-level homeostasis	BMI1 MLXIPL FLT3 IGF1R EGFR INHA DOCK10 ALAS1 BCL2 PRKDC MYB	1.14e-04	1043	57	11	GO:0048871
GeneOntologyBiologicalProcess	negative regulation of B cell differentiation	FLT3 INHA	2.67e-04	9	57	2	GO:0045578
GeneOntologyBiologicalProcess	hematopoietic stem cell differentiation	CHD2 BCL2 PRKDC	2.98e-04	47	57	3	GO:0060218
GeneOntologyBiologicalProcess	peptidyl-amino acid modification	TTBK2 MLXIPL FLT3 IGF1R EGFR BCL2 PRKDC PDPK2P PPWD1 PHIP	3.06e-04	976	57	10	GO:0018193
GeneOntologyBiologicalProcess	mononuclear cell differentiation	BMI1 FLT3 INHA DOCK10 BCL2 PRKDC BTN2A1 MYB	3.55e-04	640	57	8	GO:1903131
GeneOntologyBiologicalProcess	positive regulation of mitotic nuclear division	IGF1R PHIP CDC23	3.58e-04	50	57	3	GO:0045840
GeneOntologyBiologicalProcess	hemopoiesis	BMI1 FLT3 INHA DOCK10 CHD2 ALAS1 BCL2 PRKDC THSD1 BTN2A1 MYB	4.51e-04	1223	57	11	GO:0030097
GeneOntologyBiologicalProcess	hematopoietic or lymphoid organ development	FLT3 BCL2 PRKDC MYB	5.01e-04	133	57	4	GO:0048534
GeneOntologyBiologicalProcess	regulation of peptidyl-serine phosphorylation	MLXIPL EGFR BCL2 PHIP	5.60e-04	137	57	4	GO:0033135
GeneOntologyBiologicalProcess	pro-B cell differentiation	FLT3 PRKDC	5.74e-04	13	57	2	GO:0002328
GeneOntologyBiologicalProcess	insulin-like growth factor receptor signaling pathway	IGF1R PDPK2P PHIP	6.12e-04	60	57	3	GO:0048009
GeneOntologyBiologicalProcess	T cell differentiation	BMI1 FLT3 BCL2 PRKDC BTN2A1 MYB	6.35e-04	382	57	6	GO:0030217
GeneOntologyBiologicalProcess	thymus development	BCL2 PRKDC MYB	6.43e-04	61	57	3	GO:0048538
GeneOntologyBiologicalProcess	regeneration	XYLT1 FLT3 IGF1R EGFR BCL2	6.53e-04	252	57	5	GO:0031099
MousePheno	arrested B cell differentiation	FLT3 DOCK10 PRKDC MYB	1.27e-05	46	44	4	MP:0001802
MousePheno	abnormal spleen red pulp morphology	BMI1 FLT3 CHD2 BCL2 MYB	2.34e-05	110	44	5	MP:0002356
MousePheno	decreased pre-B cell number	FLT3 BCL2 PRKDC MYB	5.66e-05	67	44	4	MP:0008209
MousePheno	decreased mature B cell number	BMI1 FLT3 DOCK10 BCL2 PRKDC MYB	8.16e-05	232	44	6	MP:0008211
MousePheno	increased cellular sensitivity to X-ray irradiation	CHD2 PRKDC	9.62e-05	5	44	2	MP:0002879
Domain	Furin-like	IGF1R EGFR	1.90e-04	7	57	2	PF00757
Domain	Rcpt_L-dom	IGF1R EGFR	1.90e-04	7	57	2	IPR000494
Domain	Furin-like_Cys-rich_dom	IGF1R EGFR	1.90e-04	7	57	2	IPR006211
Domain	Recep_L_domain	IGF1R EGFR	1.90e-04	7	57	2	PF01030
Domain	-	IGF1R EGFR	1.90e-04	7	57	2	3.80.20.20
Domain	Ank_2	POTEB3 POTEM POTEG POTEH POTEC	4.97e-04	215	57	5	PF12796
Domain	-	POTEB3 POTEM POTEG POTEH POTEC	9.46e-04	248	57	5	1.25.40.20
Domain	ANK	POTEB3 POTEM POTEG POTEH POTEC	9.98e-04	251	57	5	SM00248
Domain	ANK_REPEAT	POTEB3 POTEM POTEG POTEH POTEC	1.03e-03	253	57	5	PS50088
Domain	Ankyrin_rpt-contain_dom	POTEB3 POTEM POTEG POTEH POTEC	1.05e-03	254	57	5	IPR020683
Domain	ANK_REP_REGION	POTEB3 POTEM POTEG POTEH POTEC	1.05e-03	254	57	5	PS50297
Domain	Ankyrin_rpt	POTEB3 POTEM POTEG POTEH POTEC	1.21e-03	262	57	5	IPR002110
Domain	Furin_repeat	IGF1R EGFR	1.36e-03	18	57	2	IPR006212
Domain	FU	IGF1R EGFR	1.36e-03	18	57	2	SM00261
Domain	TyrKc	FLT3 IGF1R EGFR	2.46e-03	88	57	3	SM00219
Domain	Tyr_kinase_cat_dom	FLT3 IGF1R EGFR	2.46e-03	88	57	3	IPR020635
Domain	PROTEIN_KINASE_TYR	FLT3 IGF1R EGFR	3.24e-03	97	57	3	PS00109
Domain	Tyr_kinase_AS	FLT3 IGF1R EGFR	3.24e-03	97	57	3	IPR008266
Domain	Ank	POTEM POTEG POTEH POTEC	5.15e-03	228	57	4	PF00023
Domain	Pkinase_Tyr	FLT3 IGF1R EGFR	7.18e-03	129	57	3	PF07714
Domain	Ser-Thr/Tyr_kinase_cat_dom	FLT3 IGF1R EGFR	8.63e-03	138	57	3	IPR001245
Pathway	BIOCARTA_TEL_PATHWAY	IGF1R EGFR BCL2	1.51e-05	17	41	3	MM1508
Pathway	BIOCARTA_TEL_PATHWAY	IGF1R EGFR BCL2	1.51e-05	17	41	3	M10401
Pathway	KEGG_MEDICUS_REFERENCE_REGULATION_OF_GF_RTK_RAS_ERK_SIGNALING_UBIQUITINATION_OF_RTK_BY_CBL	FLT3 IGF1R EGFR	5.02e-05	25	41	3	M47934
Pubmed	Two novel transcripts encoding two Ankyrin repeat containing proteins have preponderant expression during the mouse spermatogenesis.	POTEM POTEG POTEH POTEC	1.04e-10	6	58	4	17171436
Pubmed	Identification and characterization of TSAP, a novel gene specifically expressed in testis during spermatogenesis.	POTEM POTEH POTEC	1.76e-08	4	58	3	17342726
Pubmed	Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions.	FLT3 IGF1R EGFR BCL2 PRKDC	1.29e-07	71	58	5	28319113
Pubmed	Five POTE paralogs and their splice variants are expressed in human prostate and encode proteins of different lengths.	POTEB3 POTEG POTEH	1.53e-07	7	58	3	15276201
Pubmed	POTE, a highly homologous gene family located on numerous chromosomes and expressed in prostate, ovary, testis, placenta, and prostate cancer.	POTEB3 POTEH POTEC	2.45e-07	8	58	3	12475935
Pubmed	The loss of PGAM5 suppresses the mitochondrial degeneration caused by inactivation of PINK1 in Drosophila.	IRS4 PSMC6 PRKDC	1.58e-06	14	58	3	21151955
Pubmed	USP7 represses lineage differentiation genes in mouse embryonic stem cells by both catalytic and noncatalytic activities.	SHROOM4 HOXB9 DCAF12L1 INHA ETV1 DOCK10 SYN1 MAGEE1 BTN2A1	1.67e-06	674	58	9	37196079
Pubmed	Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.	IGF1R EGFR	2.73e-06	2	58	2	26554308
Pubmed	A dominant interfering Myb mutant causes apoptosis in T cells.	BCL2 MYB	2.73e-06	2	58	2	8946914
Pubmed	Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cells.	IGF1R EGFR	2.73e-06	2	58	2	17320820
Pubmed	BCL-2 expression by leukaemic blasts in a SCID mouse model of biphenotypic leukaemia associated with the t(4;11)(q21;q23) translocation.	BCL2 PRKDC	2.73e-06	2	58	2	7669664
Pubmed	Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.	IGF1R EGFR	2.73e-06	2	58	2	27105537
Pubmed	Epigenetic Regulation of Bmi1 by Ubiquitination and Proteasomal Degradation Inhibit Bcl-2 in Acute Myeloid Leukemia.	BMI1 MYB	2.73e-06	2	58	2	32453568
Pubmed	The Clinical Significance of the Insulin-Like Growth Factor-1 Receptor Polymorphism in Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation.	IGF1R EGFR	2.73e-06	2	58	2	27213344
Pubmed	IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations.	IGF1R EGFR	2.73e-06	2	58	2	23994953
Pubmed	Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3.	FLT3 BCL2	2.73e-06	2	58	2	23906301
Pubmed	Insulin activates EGFR by stimulating its interaction with IGF-1R in low-EGFR-expressing TNBC cells.	IGF1R EGFR	2.73e-06	2	58	2	25341922
Pubmed	A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer.	IGF1R EGFR	2.73e-06	2	58	2	28498434
Pubmed	Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.	IGF1R EGFR	2.73e-06	2	58	2	25617986
Pubmed	Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells.	IGF1R EGFR	2.73e-06	2	58	2	17525128
Pubmed	Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas.	IGF1R EGFR	2.73e-06	2	58	2	22700994
Pubmed	The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.	IGF1R EGFR	2.73e-06	2	58	2	24458568
Pubmed	Both epidermal growth factor and insulin-like growth factor receptors are dispensable for structural intestinal adaptation.	IGF1R EGFR	2.73e-06	2	58	2	25818318
Pubmed	Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients.	IGF1R EGFR	2.73e-06	2	58	2	23314677
Pubmed	IGF-1R and Bmi-1 expressions in lung adenocarcinoma and their clinicopathologic and prognostic significance.	BMI1 IGF1R	2.73e-06	2	58	2	23990442
Pubmed	Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase.	EGFR PRKDC	2.73e-06	2	58	2	16000298
Pubmed	Activated platelets rescue apoptotic cells via paracrine activation of EGFR and DNA-dependent protein kinase.	EGFR PRKDC	2.73e-06	2	58	2	25210793
Pubmed	Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.	IGF1R EGFR	2.73e-06	2	58	2	18829558
Pubmed	Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer.	IGF1R EGFR	2.73e-06	2	58	2	19033715
Pubmed	Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.	IGF1R EGFR	2.73e-06	2	58	2	17047074
Pubmed	Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.	IGF1R EGFR	2.73e-06	2	58	2	18949375
Pubmed	Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R.	IGF1R EGFR	2.73e-06	2	58	2	17918158
Pubmed	Study of molecular prognostic factors Bcl-2 and EGFR in rectal mucinous carcinomas.	EGFR BCL2	2.73e-06	2	58	2	22732796
Pubmed	Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.	IGF1R EGFR	2.73e-06	2	58	2	16037379
Pubmed	High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients.	IGF1R EGFR	2.73e-06	2	58	2	19153117
Pubmed	EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment.	EGFR PRKDC	2.73e-06	2	58	2	21266349
Pubmed	A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.	IGF1R EGFR	2.73e-06	2	58	2	21393993
Pubmed	Bcl-2 expression promotes B- but not T-lymphoid development in scid mice.	BCL2 PRKDC	2.73e-06	2	58	2	8133891
Pubmed	Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model.	BCL2 PRKDC	2.73e-06	2	58	2	8084613
Pubmed	Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.	IGF1R EGFR	2.73e-06	2	58	2	31758670
Pubmed	Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma.	IGF1R EGFR	2.73e-06	2	58	2	26165226
Pubmed	Computational model of EGFR and IGF1R pathways in lung cancer: a Systems Biology approach for Translational Oncology.	IGF1R EGFR	2.73e-06	2	58	2	21620944
Pubmed	Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor.	IGF1R EGFR	2.73e-06	2	58	2	15253384
Pubmed	Genome-Wide Epigenetic Landscape of Lung Adenocarcinoma Links HOXB9 DNA Methylation to Intrinsic EGFR-TKI Resistance and Heterogeneous Responses.	HOXB9 EGFR	2.73e-06	2	58	2	34036228
Pubmed	The Vertebrate Genome Annotation browser 10 years on.	POTEB3 POTEM POTEG POTEH POTEC	7.97e-06	163	58	5	24316575
Pubmed	Epidermal growth factor receptor (EGFR), HER2 and insulin-like growth factor-1 receptor (IGF-1R) status in ovarian adult granulosa cell tumours.	IGF1R EGFR	8.19e-06	3	58	2	24206174
Pubmed	High receptor tyrosine kinase (FLT3, KIT) transcript versus anti-apoptotic (BCL2) transcript ratio independently predicts inferior outcome in pediatric acute myeloid leukemia.	FLT3 BCL2	8.19e-06	3	58	2	25216797
Pubmed	The insulin-like growth factor I receptor-induced interaction of insulin receptor substrate-4 and Crk-II.	IRS4 IGF1R	8.19e-06	3	58	2	11316748
Pubmed	Threonine 2609 phosphorylation of the DNA-dependent protein kinase is a critical prerequisite for epidermal growth factor receptor-mediated radiation resistance.	EGFR PRKDC	8.19e-06	3	58	2	22923485
Pubmed	Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis.	IGF1R EGFR	8.19e-06	3	58	2	15358139
Pubmed	The EGF receptor interacts with the type 1 IGF receptor and regulates its stability.	IGF1R EGFR	8.19e-06	3	58	2	17307140
Pubmed	MiR-143-3p suppresses the progression of nasal squamous cell carcinoma by targeting Bcl-2 and IGF1R.	IGF1R BCL2	8.19e-06	3	58	2	31443963
Pubmed	Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK.	EGFR PRKDC	8.19e-06	3	58	2	18789131
Pubmed	Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.	IGF1R EGFR	8.19e-06	3	58	2	25593300
Pubmed	Evaluation of the coordinated actions of estrogen receptors with epidermal growth factor receptor and insulin-like growth factor receptor in the expression of cell surface heparan sulfate proteoglycans and cell motility in breast cancer cells.	IGF1R EGFR	8.19e-06	3	58	2	23374155
Pubmed	Molecular markers for patients with thymic malignancies: not feasible at present?	EGFR BCL2	8.19e-06	3	58	2	24870739
Pubmed	C/EBPα and MYB regulate FLT3 expression in AML.	FLT3 MYB	8.19e-06	3	58	2	23340802
Pubmed	Analysis of p53, BCL-2 and epidermal growth factor receptor protein expression in the partial and complete hydatidiform moles.	EGFR BCL2	8.19e-06	3	58	2	19348791
Pubmed	Deguelin induces apoptosis by targeting both EGFR-Akt and IGF1R-Akt pathways in head and neck squamous cell cancer cell lines.	IGF1R EGFR	8.19e-06	3	58	2	26075254
Pubmed	c-Myb is critical for murine colon development.	BCL2 MYB	8.19e-06	3	58	2	10523863
Pubmed	Co-regulation of B-Myb expression by E2F1 and EGF receptor.	EGFR MYB	8.19e-06	3	58	2	16299810
Pubmed	EGFR mutations and AKT phosphorylation are markers for sensitivity to combined MCL-1 and BCL-2/xL inhibition in non-small cell lung cancer.	EGFR BCL2	8.19e-06	3	58	2	31150457
Pubmed	Nuclear EGFR suppresses ribonuclease activity of polynucleotide phosphorylase through DNAPK-mediated phosphorylation at serine 776.	EGFR PRKDC	8.19e-06	3	58	2	22815474
Pubmed	c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells.	BMI1 MYB	8.19e-06	3	58	2	21960247
Pubmed	[Influence of transfected EGFR-cDNA on bcl-2 and Bax in glioblastoma cells].	EGFR BCL2	8.19e-06	3	58	2	12839682
Pubmed	Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.	FLT3 PDPK2P	8.19e-06	3	58	2	18184863
Pubmed	FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.	FLT3 BCL2	8.19e-06	3	58	2	34024909
Pubmed	MiR-140-3p is Involved in In-Stent Restenosis by Targeting C-Myb and BCL-2 in Peripheral Artery Disease.	BCL2 MYB	8.19e-06	3	58	2	29760303
Pubmed	The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents.	EGFR PRKDC	8.19e-06	3	58	2	23178489
Pubmed	Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer.	IGF1R EGFR	8.19e-06	3	58	2	18483367
Pubmed	Silencing of fused toes homolog enhances cisplatin sensitivity in cervical cancer cells by inhibiting epidermal growth factor receptor-mediated repair of DNA damage.	EGFR PRKDC	8.19e-06	3	58	2	27535835
Pubmed	Epidermal growth factor receptor (EGFR) abundance correlates with p53 and Bcl-2 accumulation and patient age in a small cohort of North African nasopharyngeal carcinoma patients.	EGFR BCL2	8.19e-06	3	58	2	21388911
Pubmed	Comprehensive pathway-based analysis identifies associations of BCL2, GNAO1 and CHD2 with non-obstructive azoospermia risk.	CHD2 BCL2	8.19e-06	3	58	2	24549219
Pubmed	Characterization of insulin receptor substrate 4 in human embryonic kidney 293 cells.	IRS4 IGF1R	8.19e-06	3	58	2	9553137
Pubmed	P-cadherin potentiates ligand-dependent EGFR and IGF-1R signaling in dysplastic and malignant oral keratinocytes.	IGF1R EGFR	8.19e-06	3	58	2	25322858
Pubmed	Clinical significance of proliferation, apoptosis and senescence of nasopharyngeal cells by the simultaneously blocking EGF, IGF-1 receptors and Bcl-xl genes.	IGF1R EGFR	8.19e-06	3	58	2	24055032
Pubmed	Comprehensive analysis of homeobox genes in Hodgkin lymphoma cell lines identifies dysregulated expression of HOXB9 mediated via ERK5 signaling and BMI1.	BMI1 HOXB9	8.19e-06	3	58	2	17148583
Pubmed	c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential.	IGF1R EGFR	8.19e-06	3	58	2	22343486
Pubmed	Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor.	IGF1R EGFR	8.19e-06	3	58	2	12011069
Pubmed	EGFR and IGF-1R in regulation of prostate cancer cell phenotype and polarity: opposing functions and modulation by T-cadherin.	IGF1R EGFR	8.19e-06	3	58	2	25381040
Pubmed	Multiplexing of receptor occupancy measurements for pharmacodynamic biomarker assessment of biopharmaceuticals.	IGF1R EGFR	8.19e-06	3	58	2	26332491
Pubmed	BMI1 polycomb group protein acts as a master switch for growth and death of tumor cells: regulates TCF4-transcriptional factor-induced BCL2 signaling.	BMI1 BCL2	8.19e-06	3	58	2	23671559
Pubmed	Src and epidermal growth factor receptor mediate the pro-invasive activity of Bcl-w.	EGFR BCL2	8.19e-06	3	58	2	26286833
Pubmed	Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and BCL2.	IGF1R BCL2	8.19e-06	3	58	2	25492481
Pubmed	Analysis of HSF4 binding regions reveals its necessity for gene regulation during development and heat shock response in mouse lenses.	XYLT1 ARPP21 DDX60	8.69e-06	24	58	3	18755693
Pubmed	Identification of tyrosine kinases expressed in the male mouse gubernaculum during development.	FLT3 IGF1R EGFR	9.86e-06	25	58	3	15254900
Pubmed	Epidermal growth factor receptor activation protects gastric epithelial cells from Helicobacter pylori-induced apoptosis.	EGFR BCL2	1.64e-05	4	58	2	19250983
Pubmed	Interaction in vitro of the product of the c-Crk-II proto-oncogene with the insulin-like growth factor I receptor.	IGF1R EGFR	1.64e-05	4	58	2	9480911
Pubmed	The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer.	IGF1R EGFR	1.64e-05	4	58	2	28742836
Pubmed	Engraftment of adult hematopoietic stem and progenitor cells in a novel model of humanized mice.	FLT3 PRKDC	1.64e-05	4	58	2	38433905
Pubmed	VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer.	BMI1 IGF1R	1.64e-05	4	58	2	22777769
Pubmed	Activation of Akt by advanced glycation end products (AGEs): involvement of IGF-1 receptor and caveolin-1.	IGF1R PDPK2P	1.64e-05	4	58	2	23472139
Pubmed	Platelet-Rich Plasma Promotes the Proliferation of Human Keratinocytes via a Progression of the Cell Cycle. A Role of Prolidase.	IGF1R EGFR	1.64e-05	4	58	2	33477820
Pubmed	Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb.	BCL2 MYB	1.64e-05	4	58	2	30454024
Pubmed	Prognostic importance of PTEN, EGFR, HER-2, and IGF-1R in gastric cancer patients treated with postoperative chemoradiation.	IGF1R EGFR	1.64e-05	4	58	2	31318186
Pubmed	Phosphorylation of CrkII adaptor protein at tyrosine 221 by epidermal growth factor receptor.	IGF1R EGFR	1.64e-05	4	58	2	9642287
Pubmed	Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma.	IGF1R EGFR	1.64e-05	4	58	2	20061986
Pubmed	Association of polymorphisms in FLT3, EGFR, ALOX5, and NEIL3 with glioblastoma in the Han Chinese population.	FLT3 EGFR	1.64e-05	4	58	2	24005813
Pubmed	p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme.	EGFR BCL2	1.64e-05	4	58	2	12754350
Pubmed	Role of epidermal growth factor receptor signaling in RAS-driven melanoma.	EGFR PRKDC	1.64e-05	4	58	2	15870287
Interaction	POTEG interactions	EGFR POTEG POTEH POTEC	2.80e-08	12	57	4	int:POTEG
Interaction	POTEC interactions	POTEB3 POTEG POTEC	6.01e-06	13	57	3	int:POTEC
Interaction	POTEH interactions	POTEG POTEH	7.86e-06	2	57	2	int:POTEH
Interaction	SOCS2 interactions	BMI1 FLT3 IRS4 IGF1R EGFR	8.84e-06	99	57	5	int:SOCS2
Interaction	USP7 interactions	SHROOM4 POTEB3 BMI1 HOXB9 INHA DDX60 POTEG ETV1 DOCK10 ZNF638 SYN1 MAGEE1 PHIP POTEC	1.26e-05	1313	57	14	int:USP7
Interaction	CT47A6 interactions	FLT3 EGFR	2.35e-05	3	57	2	int:CT47A6
Interaction	SOCS6 interactions	FLT3 IRS4 EGFR TUBD1 CDC23	3.31e-05	130	57	5	int:SOCS6
Interaction	URB1 interactions	ZNF668 FLT3 EGFR DDX60 CDC23	3.96e-05	135	57	5	int:URB1
Interaction	POTED interactions	POTEB3 POTEC	4.70e-05	4	57	2	int:POTED
Interaction	EIF2S2 interactions	FLT3 IGF1R EGFR DDX60 PSMC6 PRKDC	6.86e-05	247	57	6	int:EIF2S2
GeneFamily	Ankyrin repeat domain containing\|POTE ankyrin domain containing	POTEM POTEG POTEH POTEC	9.34e-09	13	36	4	685
GeneFamily	Ankyrin repeat domain containing	POTEM POTEG POTEH POTEC	1.32e-03	242	36	4	403
GeneFamily	Receptor Tyrosine Kinases\|CD molecules	FLT3 IGF1R	2.87e-03	40	36	2	321
Coexpression	GSE24671_CTRL_VS_SENDAI_VIRUS_INFECTED_MOUSE_SPLENOCYTES_UP	FAM184B IGF1R DOCK10 CHD2 PHIP	2.89e-05	161	58	5	M9446
Coexpression	WANG_IMMORTALIZED_BY_HOXA9_AND_MEIS1_UP	BMI1 ALAS1 MYB	4.87e-05	32	58	3	M1450
Coexpression	GSE38696_LIGHT_ZONE_VS_DARK_ZONE_BCELL_UP	VPS13D NOD1 CHD2 PPWD1 MYB	5.47e-05	184	58	5	M9005
Coexpression	KATSANOU_ELAVL1_TARGETS_UP	HOXB9 DCAF12L1 POTEM POTEH POTEC	6.06e-05	188	58	5	MM1071
Coexpression	GAO_LARGE_INTESTINE_ADULT_CA_ENTEROENDOCRINE_CELLS	MLXIPL FRY RAPGEF4 ETV1 TMEM63C SYN1	6.52e-05	312	58	6	M39161
Coexpression	WANG_IMMORTALIZED_BY_HOXA9_AND_MEIS1_UP	BMI1 ALAS1 MYB	7.57e-05	37	58	3	MM630
Coexpression	GSE32986_UNSTIM_VS_GMCSF_STIM_DC_UP	DDX60 ZNF638 CHD2 BCL2 MAGEE1	7.93e-05	199	58	5	M8609
Coexpression	GSE6259_FLT3L_INDUCED_33D1_POS_DC_VS_BCELL_DN	NOD1 ATP6V0D1 CHD2 PRKDC PHIP	8.12e-05	200	58	5	M6745
Coexpression	GSE21670_STAT3_KO_VS_WT_CD4_TCELL_IL6_TREATED_DN	SHROOM4 FRY PER3 INHA SIPA1L1	8.12e-05	200	58	5	M7469
ToppCell	primary_auditory_cortex_(A1C)-Non-neuronal-Macroglial-Oligo-OPC-OPC_L1-6_MYT1\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	XYLT1 SHROOM4 DDX60 DOCK10 DNAH11	4.66e-06	185	59	5	efc5d564f8793c751ba640aef60f761e4b081d3f
ToppCell	primary_auditory_cortex_(A1C)-Non-neuronal-Macroglial-Oligo-OPC\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	XYLT1 SHROOM4 DDX60 DOCK10 DNAH11	4.66e-06	185	59	5	fba2dc46cd98ab9c78e788959c2121aa10d148b2
ToppCell	Primary_Visual_cortex_(V1C)-Non-neuronal-Macroglial-Oligo-OPC\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	XYLT1 SHROOM4 DDX60 DOCK10 DNAH11	4.91e-06	187	59	5	daff7ccd3f1924cf2b34d3aca3eccde245aaf371
ToppCell	Primary_Visual_cortex_(V1C)-Non-neuronal-Macroglial-Oligo-OPC-OPC_L1-6_MYT1\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	XYLT1 SHROOM4 DDX60 DOCK10 DNAH11	4.91e-06	187	59	5	5b7a1edee602e55d3400dc17dbb6b8aaa26defc0
ToppCell	TCGA-Blood_and_Bone_Marrow-Primary_Blood_Derived_Cancer_-_Peripheral_Blood-Leukemia-Acute_Myeloid_Leukemia\|TCGA-Blood_and_Bone_Marrow / Sample_Type by Project: Shred V9	TTBK2 FLT3 PHIP MYB	6.26e-06	90	59	4	2e324fd2d2faff2b073a2726747bd283deaa8b0a
ToppCell	TCGA-Blood_and_Bone_Marrow-Primary_Blood_Derived_Cancer_-_Peripheral_Blood\|TCGA-Blood_and_Bone_Marrow / Sample_Type by Project: Shred V9	TTBK2 FLT3 PHIP MYB	6.26e-06	90	59	4	6ca41b5a618be50745bf8a83d697660847d04679
ToppCell	TCGA-Blood_and_Bone_Marrow-Primary_Blood_Derived_Cancer_-_Peripheral_Blood-Leukemia\|TCGA-Blood_and_Bone_Marrow / Sample_Type by Project: Shred V9	TTBK2 FLT3 PHIP MYB	6.26e-06	90	59	4	adfd1c3238f19939c9ff850524d166f549c4b4c3
ToppCell	NS-moderate-d_07-13-Epithelial-FOXN4+\|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	RAPGEF4 CFAP69 MYB DNAH11	5.59e-05	157	59	4	410c9d74a2085179cfb39853cb6d330fa98c9c1b
ToppCell	5'-GW_trimst-2-LargeIntestine-Epithelial-neuro-epithelial-L_cells_(PYY+)\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	MLXIPL HOXB9 ETV1 TMEM63C	7.61e-05	170	59	4	6a98f47f8c2b5b15e09169bd82eff1e6bf76e5a6
ToppCell	BAL-Mild-Epithelial-Epithelial-AT1/AT2\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	EGFR RAPGEF4 ETV1 MFSD6L	8.33e-05	174	59	4	b7f5492ce8098f7eb0aef30ee558d00738d59d0e
ToppCell	BAL-Mild-Epithelial-Epithelial-AT1/AT2-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	EGFR RAPGEF4 ETV1 MFSD6L	8.33e-05	174	59	4	cafe4d6b5f08d8888e9db6e196c66df991c03e7b
ToppCell	BAL-Mild-Epithelial-Epithelial-AT1/AT2-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	EGFR RAPGEF4 ETV1 MFSD6L	8.33e-05	174	59	4	71730503be3d9c839c4c9e950145e2101d682a1c
ToppCell	BAL-Mild-Epithelial-Epithelial-AT1/AT2\|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)	EGFR RAPGEF4 ETV1 MFSD6L	8.33e-05	174	59	4	ee8ac51fa0b426ad7b7453371bb79c8bf8c1d358
ToppCell	3'-Pediatric_IBD-SmallIntestine-Epithelial-neuro-epithelial-N_cells_(NTS+)\|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract	C17orf113 HOXB9 ETV1 SYN1	8.52e-05	175	59	4	97a58bc6ed2e8e359283d4214172c990c6e3755e
ToppCell	3'-Parenchyma_lung-Endothelial-Blood_vessel_EC-pulmonary_artery_endothelial_cell-EC_arterial-EC_arterial_L.2.4.1.3\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	FRY RAPGEF4 MAGEE1 THSD1	8.90e-05	177	59	4	16197068260fc062bf8b730a51a199887ea580b9
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1-6_LAMP5_CA13_(Lamp5_Lhx6_1)\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	EGFR DOCK10 NPFFR1 MYB	8.90e-05	177	59	4	b75f519d72611b293d9684f7dcfb1b70fbf54a90
ToppCell	Control-Myeloid-Dendritic_cells\|Control / group, cell type (main and fine annotations)	XYLT1 FLT3 DOCK10 BCL2	9.50e-05	180	59	4	25ad95c3c30e3b82abe93bd77ba003f5c2241f7c
ToppCell	TCGA-Head_and_Esophagus-Primary_Tumor-Head_and_Neck_Carcinoma-Squamous_Cell_Carcinoma-4\|TCGA-Head_and_Esophagus / Sample_Type by Project: Shred V9	UNC119B KCND1 DOCK10 BCL2	9.50e-05	180	59	4	886ebaf9cf8992e8dd13fca799a1d1a2a9ce73d8
ToppCell	CTRL-Myeloid-cDC\|CTRL / Disease state, Lineage and Cell class	XYLT1 FLT3 BCL2 NPFFR1	1.01e-04	183	59	4	20c4d16de7e090df3556a4458f783383a26871b6
ToppCell	droplet-Pancreas-Endocrine-21m-Epithelial-pancreatic_A_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FAM184B RAPGEF4 ETV1 DNAH11	1.06e-04	185	59	4	4e40d3103ebf4a7066b7ce300b6ef700ba0e2863
ToppCell	droplet-Pancreas-Endocrine-21m-Epithelial-pancreatic_A_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FAM184B RAPGEF4 ETV1 DNAH11	1.08e-04	186	59	4	16092819e9148dfe64f07c737652b6e533e699f7
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1-6_LAMP5_CA13_(Lamp5_Lhx6_1)\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	EGFR DOCK10 NPFFR1 MYB	1.08e-04	186	59	4	77592a6397b44b2b59a4fc39d7224dd95343efe6
ToppCell	facs-Brain_Non-Myeloid-Striatum-3m-Endothelial-endothelial_cell\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FRY IGF1R ALAS1 THSD1	1.12e-04	188	59	4	4dc89c7843ebd078e3414e835c56f11fa27f0c5f
ToppCell	facs-Brain_Non-Myeloid-Striatum-3m-Endothelial-Endothelial_cell\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FRY IGF1R ALAS1 THSD1	1.12e-04	188	59	4	d577b3c2a844e3062c7ca9e9ebc1722d0ac95caa
ToppCell	facs-Brain_Non-Myeloid-Striatum-3m-Endothelial\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FRY IGF1R ALAS1 THSD1	1.12e-04	188	59	4	1e788b60dd643bf220d8dfafa82d85fd083cbc71
ToppCell	droplet-Pancreas-Endocrine-18m-Epithelial-pancreatic_A_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FAM184B ETV1 BCL2 DNAH11	1.15e-04	189	59	4	ce3fbaf9642785c8adf6edaeae20998bca558928
ToppCell	LAM-Endothelial-VasEndo-1\|LAM / Condition, Lineage and Cell class	SHROOM4 FRY RAPGEF4 THSD1	1.15e-04	189	59	4	454e64b1ee93edebbc1576fbf7c3a6db332fa927
ToppCell	Control-Myeloid-cDC2\|Control / Disease state, Lineage and Cell class	XYLT1 FLT3 SIPA1L1 BCL2	1.17e-04	190	59	4	4e481e42353d47af7991744000403af2873f6a41
ToppCell	droplet-Pancreas-Endocrine-18m-Epithelial-pancreatic_A_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FAM184B ETV1 BCL2 DNAH11	1.17e-04	190	59	4	db19c72d8c8053262b535068c5a9d4d696989cb1
ToppCell	Control-Myeloid-cDC2\|World / Disease state, Lineage and Cell class	XYLT1 FLT3 SIPA1L1 BCL2	1.19e-04	191	59	4	11dfd8f38beb294f42710cfbd355cb089e1023c0
ToppCell	IPF-Myeloid-cDC2\|World / Disease state, Lineage and Cell class	XYLT1 FLT3 SIPA1L1 BCL2	1.19e-04	191	59	4	9fda87fb6bc5b8b6c0214ec909ebbc9f3f65319b
ToppCell	COPD-Myeloid-cDC2\|Myeloid / Disease state, Lineage and Cell class	XYLT1 FLT3 SIPA1L1 BCL2	1.22e-04	192	59	4	984cdc2f1d93e164bc946d63f58dacb629f82eb7
ToppCell	IPF-Myeloid-cDC2\|IPF / Disease state, Lineage and Cell class	XYLT1 FLT3 SIPA1L1 BCL2	1.22e-04	192	59	4	fe1de692fec48cba4a9bbc6eaa257260e8b4e800
ToppCell	BAL-Control-Myeloid-cDC-cDC-cDC_5\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	FLT3 SIPA1L1 BCL2 NPFFR1	1.24e-04	193	59	4	704378de39e1b6f108ab5b0ecbd594d414ec8ae4
ToppCell	Control-Endothelial-Endothelial-Gen_Cap\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	XYLT1 SHROOM4 RAPGEF4 THSD1	1.24e-04	193	59	4	e1d546165dcc2392f540162206852c4717d7306f
ToppCell	(6)_Endothelial-C_(Capillary_Aerocyte_)\|World / Lung cell shreds - cell class (v4) and cell subclass (v4)	SHROOM4 FRY RAPGEF4 THSD1	1.24e-04	193	59	4	f7f2dc6aff02d096a282835094d26d12b3b73e61
ToppCell	IPF-Myeloid-cDC2\|Myeloid / Disease state, Lineage and Cell class	XYLT1 FLT3 SIPA1L1 BCL2	1.27e-04	194	59	4	accf4b7b09e2048f2e47a52201e0158684dda8fe
ToppCell	BAL-Control-Myeloid-cDC-cDC-cDC_5\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	FLT3 SIPA1L1 BCL2 NPFFR1	1.27e-04	194	59	4	36f8ae4f2b3bf802f6ff0e9fc79e7f170f96ae8b
ToppCell	367C-Endothelial_cells-Endothelial-E\|367C / Donor, Lineage, Cell class and subclass (all cells)	SHROOM4 FRY RAPGEF4 THSD1	1.29e-04	195	59	4	3b79e6bb525b17192ecec9e1227a29c419968144
ToppCell	367C-Endothelial_cells-Endothelial-E-\|367C / Donor, Lineage, Cell class and subclass (all cells)	SHROOM4 FRY RAPGEF4 THSD1	1.29e-04	195	59	4	65fc50e3818e902028fc4226070fa57609c66b9c
ToppCell	tumor_Lung-Endothelial_cells-Tip-like_ECs\|tumor_Lung / Location, Cell class and cell subclass	SHROOM4 FRY RAPGEF4 THSD1	1.34e-04	197	59	4	353b76ca3e2aa4b8f51396e7121c4baa114083a0
ToppCell	mild-Others-CD34+_GATA2+_cells\|Others / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	UNC119B FLT3 CDC23 MYB	1.34e-04	197	59	4	a375edbc885ae069f9abcd8d5886fdaa8913f83d
ToppCell	metastatic_Brain-Endothelial_cells-Tumor_ECs\|metastatic_Brain / Location, Cell class and cell subclass	SHROOM4 FRY RAPGEF4 THSD1	1.37e-04	198	59	4	5e274f29cc796dae7d64d6035e904816c25f9914
ToppCell	metastatic_Brain-Endothelial_cells\|metastatic_Brain / Location, Cell class and cell subclass	SHROOM4 FRY RAPGEF4 THSD1	1.37e-04	198	59	4	97ef7946ef11ac93318c1dd46b548dc01e5a6aba
ToppCell	Parenchymal-10x3prime_v2-Immune_Myeloid-Dendritic_cell-DC_activated\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	XYLT1 FLT3 DOCK10 MYB	1.40e-04	199	59	4	3b2bd3caf4d189a1726a737b0121860b265eec04
ToppCell	Parenchymal-NucSeq-Immune_Myeloid-Dendritic_cell-DC_activated\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	ZNF668 FLT3 DOCK10 NPFFR1	1.40e-04	199	59	4	82759af613ebfffe037afda55159bf6af812c3ac
ToppCell	normal_Lung-Endothelial_cells-Tip-like_ECs\|normal_Lung / Location, Cell class and cell subclass	SHROOM4 FRY RAPGEF4 THSD1	1.40e-04	199	59	4	1ae0b47fade7b1cd74c0faabcf4f12f56f62264e
ToppCell	Macroglial-Polydendrocytes-PDGFRA---\|Macroglial / cells hierarchy compared to all cells using T-Statistic	XYLT1 FRY ARPP21 RAPGEF4	1.42e-04	200	59	4	4fc3de4bff7ed2bf40b38462c4b4e9b87af6a4ca
ToppCell	LPS_anti-TNF-Hematopoietic_Myeloid-Dendritic_cells-pDC\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	FLT3 DOCK10 MFSD6L MYB	1.42e-04	200	59	4	6a34e07e6d77fe3fdd9ff44c4b1e46a023f6d6a2
ToppCell	Macroglial-Polydendrocytes-PDGFRA-\|Macroglial / cells hierarchy compared to all cells using T-Statistic	XYLT1 FRY ARPP21 RAPGEF4	1.42e-04	200	59	4	f17b5a54e8f9eba9dcd0808ba4e8d275ac41bce2
ToppCell	Macroglial-Polydendrocytes-PDGFRA--\|Macroglial / cells hierarchy compared to all cells using T-Statistic	XYLT1 FRY ARPP21 RAPGEF4	1.42e-04	200	59	4	cc3409518f8b436ea92deb955e81114b3f410ff7
ToppCell	Macroglial-Polydendrocytes-PDGFRA----L1-6\|Macroglial / cells hierarchy compared to all cells using T-Statistic	XYLT1 FRY ARPP21 RAPGEF4	1.42e-04	200	59	4	310cd53db1c137f6af74e6ae682221d7ac27310c
ToppCell	Macroglial-Polydendrocytes-PDGFRA\|Macroglial / cells hierarchy compared to all cells using T-Statistic	XYLT1 FRY ARPP21 RAPGEF4	1.42e-04	200	59	4	c24a3099e3d96d8b72f6d05286bb355d661a0377
ToppCell	Macroglial-Polydendrocytes\|Macroglial / cells hierarchy compared to all cells using T-Statistic	XYLT1 FRY ARPP21 RAPGEF4	1.42e-04	200	59	4	961858738ce35db8760c8c2e136f8369bc444ccf
ToppCell	Parenchymal-NucSeq-Immune_Myeloid-Monocytic-Monocyte_CD14\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	XYLT1 FLT3 DOCK10 SYN1	1.42e-04	200	59	4	b4277b6faa69f20974696c7c422311f5c89e3663
Drug	secoisolariciresinol diglucoside	IGF1R EGFR BCL2	4.90e-07	7	56	3	ctd:C090142
Drug	NVP-AEW541	IGF1R EGFR BCL2	7.72e-06	16	56	3	ctd:C501177
Drug	Thiocolchicoside [602-41-5]; Up 200; 7uM; MCF7; HT_HG-U133A	VPS13D IGF1R EGFR INHA DLGAP4 BCL2	8.31e-06	195	56	6	2875_UP
Drug	clofibrate; Down 200; 150uM; MCF7; HG-U133A	ZNF668 EGFR SIPA1L1 CHD2 THSD1 TUBD1	8.81e-06	197	56	6	263_DN
Drug	Bemegride [64-65-3]; Down 200; 25.8uM; HL60; HT_HG-U133A	ZNF668 HOXB9 SIPA1L1 TUBD1 CFAP69 NPFFR1	9.07e-06	198	56	6	3051_DN
Drug	Monensin sodium salt [22373-78-0]; Down 200; 5.8uM; HL60; HT_HG-U133A	VPS13D PER3 DDX60 SIPA1L1 TUBD1 CFAP69	9.07e-06	198	56	6	2580_DN
Drug	SB 203580; Up 200; 1uM; PC3; HT_HG-U133A	PER3 INHA ETV1 BCL2 CA5B CFAP69	9.60e-06	200	56	6	6894_UP
Drug	Vapreotide	IGF1R EGFR BCL2 PRKDC	2.38e-05	68	56	4	CID000071306
Drug	indibulin	EGFR BCL2 TUBD1	3.52e-05	26	56	3	CID000002929
Drug	3-quinolinecarbonitrile	IGF1R EGFR	5.91e-05	5	56	2	CID000093177
Drug	SC-203048	FLT3 BCL2	5.91e-05	5	56	2	ctd:C572332
Drug	Anthraquinones	IGF1R EGFR BCL2	6.65e-05	32	56	3	ctd:D000880
Drug	Selegiline hydrochloride [14611-52-0]; Up 200; 17.8uM; MCF7; HT_HG-U133A	VPS13D KCND1 DDX60 DOCK10 CFAP69	1.12e-04	193	56	5	4146_UP
Drug	AC1L1GUZ	FLT3 EGFR MYB	1.12e-04	38	56	3	CID000003852
Drug	S(-)Eticlopride hydrochloride [97612-24-3]; Up 200; 10.6uM; MCF7; HT_HG-U133A	HOXB9 EGFR DDX60 ETV1 CFAP69	1.15e-04	194	56	5	5695_UP
Drug	Tiletamine hydrochloride; Down 200; 15.4uM; MCF7; HT_HG-U133A	VPS13D EGFR SIPA1L1 NPFFR1 BTN2A1	1.15e-04	194	56	5	6516_DN
Drug	Terconazole [67915-31-5]; Down 200; 7.6uM; MCF7; HT_HG-U133A	TTBK2 PER3 EGFR THSD1 NPFFR1	1.20e-04	196	56	5	4407_DN
Drug	Amiodarone hydrochloride [19774-82-4]; Up 200; 5.8uM; MCF7; HT_HG-U133A	IRS4 NOD1 EGFR CFAP69 NPFFR1	1.23e-04	197	56	5	5618_UP
Drug	Tetracaone hydrochloride [136-47-0]; Up 200; 13.2uM; MCF7; HT_HG-U133A	EGFR DDX60 SIPA1L1 DOCK10 NPFFR1	1.23e-04	197	56	5	2888_UP
Drug	Betulin [473-98-3]; Up 200; 9uM; MCF7; HT_HG-U133A	MLXIPL VPS13D SIPA1L1 BCL2 NPFFR1	1.23e-04	197	56	5	7454_UP
Drug	Ajmalicine hydrochloride [4373-34-6]; Up 200; 10.2uM; MCF7; HT_HG-U133A	VPS13D EGFR SIPA1L1 DOCK10 NPFFR1	1.23e-04	197	56	5	2898_UP
Drug	pioglitazone HCl; Up 200; 10uM; MCF7; HT_HG-U133A	NOD1 DLGAP4 RAPGEF4 CA5B CFAP69	1.23e-04	197	56	5	5972_UP
Drug	Clozapine [5786-21-0]; Up 200; 12.2uM; MCF7; HT_HG-U133A	HOXB9 NOD1 DLGAP4 CFAP69 NPFFR1	1.23e-04	197	56	5	5630_UP
Drug	Suramin sodium salt; Up 200; 10uM; PC3; HT_HG-U133A	VPS13D NOD1 EGFR DDX60 BTN2A1	1.23e-04	197	56	5	7529_UP
Drug	Gold Compounds	EGFR BCL2	1.24e-04	7	56	2	ctd:D017612
Drug	RU 58668	IGF1R BCL2	1.24e-04	7	56	2	ctd:C086511
Drug	Nalidixic acid sodium salt hydrate; Down 200; 14.6uM; MCF7; HT_HG-U133A	ZNF668 SIPA1L1 BCL2 THSD1 NPFFR1	1.26e-04	198	56	5	2297_DN
Drug	PHA-00767505E [723337-45-9]; Up 200; 10uM; MCF7; HT_HG-U133A	TTBK2 NOD1 DOCK10 THSD1 NPFFR1	1.26e-04	198	56	5	6550_UP
Drug	Dioxybenzone [131-53-3]; Up 200; 16.4uM; HL60; HT_HG-U133A	MLXIPL ZNF668 KCND1 ETV1 NPFFR1	1.29e-04	199	56	5	3101_UP
Drug	Zaprinast [37762-06-4]; Up 200; 14.8uM; MCF7; HT_HG-U133A	MLXIPL EGFR KCND1 SIPA1L1 MYB	1.29e-04	199	56	5	3226_UP
Drug	Ceftazidime pentahydrate [78439-06-2]; Down 200; 6.2uM; PC3; HT_HG-U133A	VPS13D NOD1 PER3 THSD1 CA5B	1.29e-04	199	56	5	5054_DN
Drug	Aminohippuric acid [61-78-9]; Up 200; 20.6uM; PC3; HT_HG-U133A	VPS13D NOD1 ETV1 DOCK10 CFAP69	1.32e-04	200	56	5	6294_UP
Drug	Promazine hydrochloride [53-60-1]; Up 200; 12.4uM; PC3; HT_HG-U133A	FLT3 IGF1R ETV1 CA5B MYB	1.32e-04	200	56	5	3752_UP
Disease	B-lymphoblastic leukemia/lymphoma (is_marker_for)	FLT3 MYB	1.89e-05	4	53	2	DOID:0080630 (is_marker_for)
Disease	Squamous cell carcinoma of lung	IGF1R EGFR PRKDC	2.62e-05	32	53	3	C0149782
Disease	platelet crit	FAM184B FLT3 IGF1R EGFR KCND1 ETV1 DOCK10 BCL2 MYB	4.52e-05	952	53	9	EFO_0007985
Disease	mean reticulocyte volume	UNC119B MLXIPL FLT3 NOD1 ZNF638 BCL2 TUBD1 MYB	8.42e-05	799	53	8	EFO_0010701
Disease	Acute erythroleukemia - M6a subtype	FLT3 HOXB9	8.80e-05	8	53	2	C2930975
Disease	Acute myeloid leukemia FAB-M6	FLT3 HOXB9	8.80e-05	8	53	2	C2930976
Disease	Acute erythroleukemia - M6b subtype	FLT3 HOXB9	8.80e-05	8	53	2	C2930977
Disease	Acute erythroleukemia	FLT3 HOXB9	8.80e-05	8	53	2	C2930974
Disease	Headache, glucose measurement	IGF1R ZNF638	1.13e-04	9	53	2	EFO_0004468, HP_0002315
Disease	Malignant neoplasm of breast	ZNF668 HOXB9 IGF1R PER3 EGFR SIPA1L1 PPHLN1 BCL2 MAGEE1	1.14e-04	1074	53	9	C0006142
Disease	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	FLT3 BCL2 MYB	1.20e-04	53	53	3	C1961099
Disease	mean corpuscular hemoglobin concentration	UNC119B TTBK2 MLXIPL EGFR DLGAP4 ZNF638 BCL2 PRKDC MYB	1.41e-04	1105	53	9	EFO_0004528
Disease	gallbladder neoplasm	EGFR BCL2	1.72e-04	11	53	2	C0016978
Disease	Malignant neoplasm of gallbladder	EGFR BCL2	1.72e-04	11	53	2	C0153452
Disease	acute kidney failure (biomarker_via_orthology)	IGF1R EGFR BCL2	1.83e-04	61	53	3	DOID:3021 (biomarker_via_orthology)
Disease	Lung diseases	IGF1R PRKDC DNAH11	3.78e-04	78	53	3	C0024115
Disease	hypertrophic cardiomyopathy (is_marker_for)	IGF1R BCL2	4.23e-04	17	53	2	DOID:11984 (is_marker_for)
Disease	acute myeloid leukemia (is_implicated_in)	BMI1 FLT3 BCL2	4.70e-04	84	53	3	DOID:9119 (is_implicated_in)
Disease	Adrenocortical carcinoma	IGF1R EGFR	4.75e-04	18	53	2	C0206686
Disease	Glioma	BMI1 EGFR MYB	5.21e-04	87	53	3	C0017638
Disease	thrombin activatable fibrinolysis inhibitor activation peptide measurement	ARPP21 DOCK10	5.31e-04	19	53	2	EFO_0008582
Disease	left ventricular structural measurement	IGF1R SIPA1L1 PHIP	5.39e-04	88	53	3	EFO_0008205
Disease	Weight Gain	VPS13D SIPA1L1 DNAH11	8.29e-04	102	53	3	C0043094
Disease	Head Neoplasms	EGFR BCL2	8.52e-04	24	53	2	C0018675
Disease	Upper Aerodigestive Tract Neoplasms	EGFR BCL2	8.52e-04	24	53	2	C0887900
Disease	Cancer of Head	EGFR BCL2	8.52e-04	24	53	2	C0751177
Disease	Neck Neoplasms	EGFR BCL2	9.25e-04	25	53	2	C0027533
Disease	Left ventricular mass to end-diastolic volume ratio	IGF1R SIPA1L1	9.25e-04	25	53	2	EFO_0010556
Disease	Cancer of Neck	EGFR BCL2	9.25e-04	25	53	2	C0746787
Disease	immature platelet count	DOCK10 BCL2 MYB	9.26e-04	106	53	3	EFO_0803544
Disease	basophil percentage of leukocytes	BCL2 PRKDC TUBD1 MYB	9.57e-04	243	53	4	EFO_0007992
Disease	glucose metabolism disease (implicated_via_orthology)	IRS4 IGF1R	1.16e-03	28	53	2	DOID:4194 (implicated_via_orthology)
Disease	prostate cancer (is_implicated_in)	FLT3 EGFR BCL2	1.23e-03	117	53	3	DOID:10283 (is_implicated_in)
Disease	granulocyte percentage of myeloid white cells	MLXIPL FLT3 DOCK10 PRKDC	1.37e-03	268	53	4	EFO_0007997
Disease	Head and Neck Neoplasms	EGFR BCL2	1.61e-03	33	53	2	C0018671
Disease	basophil count	FLT3 BCL2 PRKDC TUBD1 MYB	1.73e-03	483	53	5	EFO_0005090

Protein segments in the cluster

Peptide	Gene	Start	Entry
PLMNRTVRSSFRHDY	CA5B	286	Q9Y2D0
YYRRAHQLRPNDSRM	CDC23	421	Q9UJX2
ERFSQGSHRDYRVFM	DNAH11	4006	Q96DT5
GRQAERSQPRYFMHA	DLGAP4	231	Q9Y2H0
QNRMHPFRDDRRSKS	ARPP21	266	Q9UBL0
TEHGDYYSPRRVRDM	C17orf113	166	A0A1B0GUU1
EHHFMVDARNRSYPL	NPFFR1	186	Q9GZQ6
RDPDMFRHVLNFYRT	KCND1	86	Q9NSA2
DPRNHSYTLYNRREM	MAGEE1	806	Q9HCI5
TVNRRAHIFPMADDY	ALAS1	221	P13196
RRFHYAAFPSAMSHR	FAM184B	931	Q9ULE4
MKRRRDFYAAHPSAD	BMI1	91	P35226
SLRMYHRFLGNREPS	DDX60	271	Q8IY21
DDQRRHAMRGRLFYT	TMEM63C	266	Q9P1W3
LRASFDERQPYAHMN	IGF1R	1336	P08069
RMERALSALFRGHFY	MFSD6L	486	Q8IWD5
LAPQDMRVFYAHTAR	PER3	171	P56645
PDSSYPMDHRFRRQL	ETV1	176	P50549
GFSPSHLRAYARRMF	NOD1	351	Q9Y239
MARRPRHSIYSSDED	MYB	1	P10242
TRERDVMSRLDHPFF	PDPK2P	101	Q6A1A2
FNMYLTRDRRHEVAR	HOXB9	206	P17482
SAFMEPRYHVRREDL	POTEB3	126	A0JP26
SRRMASQHSYPLNRF	CBY2	81	Q8NA61
PHTYQNRRPFSREMD	FLT3	966	P36888
RMHLPSPTDSNFYRA	EGFR	986	P00533
NLMAKHSFDDRYREP	DOCK10	1181	Q96BY6
YHQQDFRRMSDHRPA	CHD2	1736	O14647
MRDRSHIYTCPRSAF	BTN2A1	466	Q7KYR7
FRYMFRPSQHTRSRQ	INHA	111	P05111
RQRRPATYRSMAHYL	DCAF12L1	41	Q5VU92
IMFTPLDRYSDRNHQ	FRY	1136	Q5TBA9
LFMRGFSHYDRQLRN	CFAP69	296	A5D8W1
HSASRQPEYRDMRDG	PPHLN1	91	Q8NEY8
ADRHPERRMRAAFTA	CCDC124	161	Q96CT7
SAFMEPRYHVRREDL	POTEC	126	B2RU33
RHSRSPFEDSRGYMM	IRS4	731	O14654
RQHAFSMARNGDYRS	SYN1	186	P17600
FESLMDPSRNHRAYR	RAPGEF4	896	Q8WZA2
RHDRPYTLSMANAGS	PPWD1	571	Q96BP3
TPKVHTDDFYMRRFR	SIPA1L1	26	O43166
SSCRELRRHPMDQSY	SHROOM4	816	Q9ULL8
RDMFDDYVRTRTLHN	MLXIPL	751	Q9NP71
RRYRRDFAEMSSQLH	BCL2	106	P10415
ESSFHYRRNPLGDLM	TUBD1	246	Q9UJT1
RYRDMNFLKSHGRDN	XYLT1	441	Q86Y38
GRMFSDPSSFRRHQR	ZNF668	286	Q96K58
MFFHSDYRPLIRDAN	PHIP	556	Q8WWQ0
FHEARQARPFRERSM	THSD1	656	Q9NS62
RYASINAHRNREMGR	TTBK2	191	Q6IQ55
PVSNFRMIERHYFRE	UNC119B	166	A6NIH7
YSIMVHALRAFRSDP	PRKDC	3981	P78527
SARLIREMFNYARDH	PSMC6	211	P62333
SAFMEPRYHVRREDL	POTEG	126	Q6S5H5
DDSAFMEPRYHVRRE	POTEH	161	Q6S545
SAFMEPRYHVRREDL	POTEM	126	A6NI47
SSHRFRRSRSPMHYM	ZNF638	501	Q14966
EFRHMRNHAYEPLAS	ATP6V0D1	81	P61421
MLYERNPAHSHFERR	VPS13D	611	Q5THJ4